Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Theophylline Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers

NCT01530464
View directory record Official record
Conditions
High Altitude Pulmonary Hypertension
Interventions
Aminophylline, Ambrisentan, Aminophylline plus ambrisentan
Drug
Lead sponsor
Thies Schroeder
Other
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

Smell Changes & Efficacy of Nasal Theophylline

NCT03990766
View directory record Official record
Conditions
Olfactory Disorder, Anosmia, Viral Infection, Theophylline Causing Adverse Effects in Therapeutic Use, Smell Disorder
Interventions
Theophylline, Saline Nasal
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 2 Interventional

Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia

NCT00003808
View directory record Official record
Conditions
Leukemia
Interventions
theophylline
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
68
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Drug Combination on Exercise Performance at High Altitude

NCT01902758
View directory record Official record
Conditions
Acute Mountain Sickness
Interventions
ambrisentan and theophylline, placebo
Drug
Lead sponsor
University of Montana
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Not applicable Interventional Results available

Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant

NCT01759862
View directory record Official record
Conditions
Function of Renal Transplant
Interventions
Aminophylline, Theophylline drug levels, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 2, 2026, 1:33 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Theophylline for Depression Study

NCT04309877
View directory record Official record
Conditions
Depression
Interventions
Theophylline ER, PO placebo, Lipopolysaccharide (LPS), IV placebo
Drug · Other · Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 2, 2026, 1:33 AM EDT
Active, not recruiting Phase 2 Interventional

Theophylline Treatment for Pseudohypoparathyroidism

NCT03029429
View directory record Official record
Conditions
Pseudohypoparathyroidism, Albright Hereditary Osteodystrophy
Interventions
Theophylline, Placebos
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
13 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

Helping Olfaction and Nutrition On Renal Replacement

NCT02479451
View directory record Official record
Conditions
End Stage Renal Disease, Olfactory Disorders
Interventions
Theophylline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Evaluation of Aminophylline and Methazolamide

NCT01587027
View directory record Official record
Conditions
Mountain Sickness
Interventions
Aminophylline, Methazolamide, Aminophylline and Methazolamide
Drug
Lead sponsor
Poudre Valley Health System
Other
Eligibility
18 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Early Phase 1 Interventional

Study of BCG + Aminophylline Toxicity When Used in the Treatment of Bladder Cancer

NCT01240824
View directory record Official record
Conditions
Bladder Cancer
Interventions
aminophylline
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2014 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Tigulixostat on the Pharmacokinetics of Theophylline

NCT06189404
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
Tigulixostat, Theophylline
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 4 Interventional

Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers

NCT02537691
View directory record Official record
Conditions
Asthma
Interventions
FP, LABA, LTRA, LAMA, Theophylline, Oral Corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Birmingham, Alabama • Mission Viejo, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Results available

A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial

NCT01696214
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone 250 mg/salmeterol 50 mg, Montelukast 10mg, Theophylline 400 mg, ipratropium
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude

NCT01794078
View directory record Official record
Conditions
Acute Mountain Sickness and Fatigue
Interventions
Aminophylline 400 mg, Ambrisentan 5 mg, Placebo
Drug · Other
Lead sponsor
Robert J Noveck, M.D.
Other
Eligibility
18 Years to 50 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2015 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Not applicable Interventional Results available

Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery

NCT01245595
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Day to 18 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Results available

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data

NCT04606264
View directory record Official record
Conditions
Perioperative Optimization
Interventions
Neuraxial Analgesia, Regional Block 1: Paravertebral, Perphenazine, Aprepitant, Dimenhydrinate, Ondansetron 4 MG, Dexamethasone, Regional Block 2: QL1
Drug
Lead sponsor
Jennifer Holder-Murray
Other
Eligibility
18 Years and older
Enrollment
3,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 2, 2026, 1:33 AM EDT
Recruiting Phase 4 Interventional

Effect of Theophylline in Pseudohypoparathyroidism

NCT03718403
View directory record Official record
Conditions
PHP Ia, PHP IB, Php1C
Interventions
Theophylline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 2, 2026, 1:33 AM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Theophylline for Treatment of Pseudohypoparathyroidism

NCT04240821
View directory record Official record
Conditions
Pseudohypoparathyroidism, Pseudohypoparathyroidism Type 1a, Albright Hereditary Osteodystrophy
Interventions
Theophylline ER
Drug
Lead sponsor
Jaclyn Tamaroff
Other
Eligibility
2 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 2, 2026, 1:33 AM EDT
Not listed Phase 3 Interventional

Preventing Acute Kidney Injury (AKI) in Pediatric Patients

NCT03897335
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2022 · Synced Sep 2, 2026, 1:33 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage

NCT05853601
View directory record Official record
Conditions
Acute Kidney Injury, HIE
Interventions
Single Dose Theophylline, Repeat Dose Theophylline
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Hour to 18 Hours
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)

NCT02463409
View directory record Official record
Conditions
Pseudohypoparathyroidism Type 1a, Albright Hereditary Osteodystrophy
Interventions
Theophylline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
10 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

NCT00413166
View directory record Official record
Conditions
Acute Promyelocytic Leukemia
Interventions
All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), Idarubicin, Gemtuzumab Ozogamicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)

NCT05947643
View directory record Official record
Conditions
COVID-19
Interventions
theophylline, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 2, 2026, 1:33 AM EDT